Search Results - Andric, Z.G.

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)

    161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC) by Rudin, C.M., Dowlati, A., Chen, Y., Mendivil, A.F. Navarro, Yang, J.C-H., Stojanovic, G., Rich, P., Andric, Z.G., Wu, Y-L., Chen, H., Zhang, L., Yeung, S., Benzaghou, F.M., Paz-Ares, L., Bunn, P.A.

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

    103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) by Andric, Z.G., Gálffy, G., Dols, M. Cobo, Szima, B., Stojanovic, G., Petrovic, M.D., Font, E. Felip, Baz, D. Vicente, Aix, S. Ponce, Juan-Vidal, O., Tehenes, S., Szalai, Z., Losonczy, G., Blanco, A. Calles, Bernabe, R., Duecker, K., Zhou, D., Schroeder, A., Guezel, G., Ciardiello, F.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    181P SELECT: A phase II randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts)

    181P SELECT: A phase II randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts) by Gumus, M., Sukalinskaya, A., Andric, Z.G., Cheshuk, V., Ciuleanu, T-E., Sezgin Goksu, S., Cil, T., Cicin, I., Bulat, I.V., Ostapenko, Y.V., Penkov, K.D., Hart, C., Lai, M., Chaao, B., Jimenez, J., Sepahi, A., Shi, G., Trott, S., Hooper, E.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: